Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea.
Department of Surgery, College of Medicine, Chungbuk National University, Cheongju, South Korea.
Int J Cancer. 2019 Jan 15;144(2):380-388. doi: 10.1002/ijc.31849. Epub 2018 Nov 13.
The most common symptom of bladder cancer (BC) is hematuria. However, not all patients with hematuria are diagnosed with BC. Here, we explored a novel method to discriminate BC from hematuria under nonmalignant conditions by measuring differences in urinary cell-free microRNA (miRNA) expression between patients with BC and those with hematuria. A multicenter study was performed using 543 urine samples obtained from the National Biobank of Korea, including 326 BC, 174 hematuria and 43 pyuria without cancer. The urinary miR-6124 to miR-4511 ratio was considerably higher in BC than in hematuria or pyuria, and enabled the discrimination of BC from patients with hematuria at a sensitivity of >90% (p < 0.001). Conclusively, the proposed noninvasive diagnostic tool based on the expression ratio of urinary cell-free miR-6124 to miR-4511 can reduce unnecessary cystoscopies in patients with hematuria undergoing evaluation for BC, with a minimal loss in sensitivity for detecting cancer.
膀胱癌（BC）最常见的症状是血尿。然而，并非所有血尿患者都被诊断为 BC。在这里，我们通过测量 BC 患者和血尿患者尿液中无细胞游离 microRNA（miRNA）表达的差异，探索了一种在非恶性情况下区分 BC 和血尿的新方法。一项多中心研究使用了来自韩国国家生物银行的 543 个尿液样本，其中包括 326 例 BC、174 例血尿和 43 例无癌症的脓尿。与血尿或脓尿相比，BC 患者的尿液 miR-6124 到 miR-4511 的比值明显更高，并且能够以 >90%的灵敏度（p < 0.001）区分 BC。总之，基于尿液无细胞游离 miR-6124 到 miR-4511 的表达比值的这种非侵入性诊断工具可以减少血尿患者在评估 BC 时进行不必要的膀胱镜检查，同时对癌症的检测灵敏度损失最小。
